Tumor volume change after chemotherapy as a predictive factor of disease free survival for osteosarcoma

Yonsei Medical Journal

Volumn 46, Issue 1, 2005, Pages 119-124

  Moon, Seong Hwan ^a   Shin, Kyoo Ho ^a   Suh, Jin Suck ^a   Yang, Woo Ick ^a   Noh, Jae Keong ^b   Hahn, Soo Bong ^a  

^a Yonsei University   (South Korea)

^b Yonsei University College of Medicine   (South Korea)

Author keywords

Osteosarcoma; Prognostic factor; Volume

Indexed keywords

CISPLATIN; DOXORUBICIN; GADOLINIUM PENTETATE;

ARTHRODESIS; ARTICLE; BONE SCINTISCANNING; CANCER COMBINATION CHEMOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; CONFIDENCE INTERVAL; DRUG DOSE REGIMEN; FOLLOW UP; HISTOPATHOLOGY; HUMAN; KAPLAN MEIER METHOD; LEG AMPUTATION; METASTASIS; NUCLEAR MAGNETIC RESONANCE IMAGING; OSTEOSARCOMA; POSTOPERATIVE CARE; PREDICTION; PREOPERATIVE TREATMENT; PROSTHESIOLOGY; RETROSPECTIVE STUDY; SURVIVAL RATE; SURVIVAL TIME; THORAX RADIOGRAPHY; THREE DIMENSIONAL IMAGING; TUMOR NECROSIS; TUMOR VOLUME;

EID: 14944368255     PISSN: 05135796     EISSN: None     Source Type: Journal    
DOI: 10.3349/ymj.2005.46.1.119     Document Type: Article

References (21)

1. Glasser DB, Lane JM, Huvos AG, Marcove RC, Rosen G. Survival, prognosis, and therapeutic response in osteogenic sarcoma. Cancer 1992;69:698-708.
2. Bacci G, Ferrari S, Delepine N, Bertoni F, Picci P, Mercuri M, et al. Predictive factors of histologic response to primary chemotherapy in osteosarcoma of the extremity: Study of 272 patients preoperatively treated with high-dose methotrexate, doxorubicin, and cisplatin. J Clin Oncol 1998;16:658-63.
3. Goorin AM, Abelson HT, Frei III E. Osteosarcoma: Fifteen years later. N Engl J Med 1985;313:1637-41.
4. Rosen G, Caparros B, Huvos AG, Kosloff C, Nirenberg A, Cacavio A, et al. Preoperative chemotherapy for osteogenic sarcoma: selection of postoperative adjuvant chemotherapy based on the response of the primary tumor to preoperative chemotherapy. Cancer 1982;49: 1221-30.
5. Rosen G, Murphy ML, Huvos AG, Gutierrez M, Marcove RC. Chemotherapy, en bloc resection and prosthetic bone replacement in the treatment of osteogenic sarcoma. Cancer 1976;37:1-11.
6. Bieling P, Rehan N, Winkler P, Helmke K, Maas R, Fuchs N, et al. Tumor size and prognosis in aggressively treated osteosarcoma. J Clin Oncol 1996;14:848-58.
7. Bronstrom LA, Strander H, Nilsonne U. Survival on osteosarcoma in relation to tumor size and location. Clin Orthop 1982;167:250-4.
8. Hudson M, Jaffe R, Jaffe N, Ayala A, Raymond AK, Carrasco H, et al. Pediatric osteosarcoma: Therapeutic strategies, results, and prognostic factors derived from a 10-year experience. J Clin Oncol 1990;8:1988-97.
9. Meyers PA, Heller G, Healey J, Huvos A, Lane J, Marcove R, et al. Chemotherapy for nonmetastatic osteosarcoma. The Memorial Sloan-Kettering experience. J Clin Oncol 1992;10:5-15.
10. Pochanugool L, Subhadharaphandou T, Dhanachai M, Hathirat P, Sangthawan D, Pirabul R, et al. Prognostic factor among 130 patients with osteosarcoma. Clin Orthop 1997;345:206-14.
11. Scranton P, DeCicco F, Totten T, Yunis EJ. Prognostic factors in osteosarcoma: A review of 20 years experience at the University of Pittsburgh Health Center hospital. Cancer 1975;36:2179-91.
12. Taylor WF, Ivins JC, Dahlin DC, Edmonson JH, Pritchard DJ, et al. Trends and variability in survival from osteosarcoma. Mayo Clin Proc 1978;53:695-700.
13. Holscher HC, Bloem JL, Van der Woude HJ, Hermans J, Nooy MA, Taminiau AH, et al. Can MRI predict the histopathologic response in patients with osteosarcoma after the first cycle of chemotherapy? Clin Radiol 1995; 50:384-90.
14. Shin KH, Moon S-H, Suh J-S, Yang WI. Tumor volume change as a predictor of chemotherapeutic response in osteosarcoma. Clin Orthop 2000;376:200-8.
15. Enneking WF, Spanier SS, Goodman M. Current concepts review: Surgical staging of musculoskeletal sarcoma. J Bone Joint Surg Am 1980;62:1027-30.
16. Du Bois D, Du Bois EF. A formula to estimate the approximate surface area if height and weight be known. 1916 (classical article). Nutrition 1989;5:303-11.
17. Huvos AG, Rosen G, Marcove RC. Primary osteogenic sarcoma: Pathologic aspects in 20 patients after treatment with chemotherapy, en bloc resection, and prosthetic bone replacement. Arch Pathol Lab Med 1977; 101:14-8.
18. Erlemann R, Sciuk J, Bosse A, Ritter J, Kusnierz-Glaz CR, Peters PE, et al. Response of osteosarcoma and Ewing sarcoma to preoperative chemotherapy: Assessment with dynamic and static MR imaging and skeletal scintigraphy. Radiology 1990;175:791-6.
19. Holscher HC, Bloem JL, Nooy MA, Taminiau AH, Eulderink F, Hermans J, et al. The value of MR imaging in monitoring the effect of chemotherapy on bone sarcoma. Am J Roentgenol 1990;154:763-9.
20. Welling RM, Davies AM, Pynsent PB, Carter SR, Grimer RJ. The value of computed tomographic measurements in osteosarcoma as a predictor of response to adjuvant chemotherapy. Clin Radiol 1994;49:19-23.
21. Hanna J, Parham DM, Fairclough DL, Meyer WH, Le AH, Fletcher BD, et al. Assessment of osteosarcoma response to preoperative chemotherapy using dynamic FLASH gadolinium-DTPA-enhanced magnetic resonance mapping. Invest Radiol 1992;27:367-73.